title: Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity.
abstract: Regulatory T (Treg) cells expressing the transcription factor Foxp3 have a pivotal role in maintaining immunological self-tolerance; yet, excessive Treg cell activities suppress anti-tumour immune responses. Compared to the resting Treg (rTreg) cell phenotype in secondary lymphoid organs, Treg cells in non-lymphoid tissues exhibit an activated Treg (aTreg) cell phenotype. However, the function of aTreg cells and whether their generation can be manipulated are largely unexplored. Here we show that the transcription factor Foxo1, previously demonstrated to promote Treg cell suppression of lymphoproliferative diseases, has an unexpected function in inhibiting aTreg-cell-mediated immune tolerance in mice. We find that aTreg cells turned over at a slower rate than rTreg cells, but were not locally maintained in tissues. aTreg cell differentiation was associated with repression of Foxo1-dependent gene transcription, concomitant with reduced Foxo1 expression, cytoplasmic localization and enhanced phosphorylation at the Akt sites. Treg-cell-specific expression of an Akt-insensitive Foxo1 mutant prevented downregulation of lymphoid organ homing molecules, and impeded Treg cell homing to non-lymphoid organs, causing CD8(+) T-cell-mediated autoimmune diseases. Compared to Treg cells from healthy tissues, tumour-infiltrating Treg cells downregulated Foxo1 target genes more substantially. Expression of the Foxo1 mutant at a lower dose was sufficient to deplete tumour-associated Treg cells, activate effector CD8(+) T cells, and inhibit tumour growth without inflicting autoimmunity. Thus, Foxo1 inactivation is essential for the migration of aTreg cells that have a crucial function in suppressing CD8(+) T-cell responses; and the Foxo signalling pathway in Treg cells can be titrated to break tumour immune tolerance preferentially.
authors.affiliation: Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.|Louis V. Gerstner Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
authors.forename: Chong T
authors.initials: CT
authors.lastname: Luo
authors.affiliation: New York Genome Center, New York, New York 10013, USA.
authors.forename: Will
authors.initials: W
authors.lastname: Liao
authors.affiliation: Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
authors.forename: Saida
authors.initials: S
authors.lastname: Dadi
authors.affiliation: Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Toure
authors.affiliation: Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
authors.forename: Ming O
authors.initials: MO
authors.lastname: Li
mesh_terms: D000818:Animals; D015551:Autoimmunity / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002454:Cell Differentiation; D002465:Cell Movement / Q000276:immunology; D015536:Down-Regulation; D005260:Female; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D007108:Immune Tolerance / Q000276:immunology*; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D008297:Male; D051379:Mice; D009154:Mutation; D009369:Neoplasms / Q000276:immunology*; D010766:Phosphorylation; D015398:Signal Transduction / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000276:immunology* / Q000378:metabolism*; D014158:Transcription, Genetic
chemical_list: D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors; C467200:Foxo1 protein, mouse